Mycotoxin Test Results: What the Number Can and Cannot Prove

A urine panel came back positive twice over. Ochratoxin read 2.8 parts per billion against the lab’s line of 2.0, and trichothecenes read 0.4 against a line of 0.2. A crew then stripped drywall, carpet and ceiling tiles from the building and found no water damage and no significant fungal growth, at a cost to the building manager of more than twenty-five thousand dollars.

That is the whole problem with the mycotoxin test as usually sold. It is a measurement problem, not a biology problem. The compounds are real. The number on the report has nothing standing under it.

I am Dr. Gurpreet Singh Padda, MD, MBA, MHP, coauthor of The Angry Gut with Ami Michelle Grimes. In the video Mold Illness: Fix the Basement, Skip the Panel, I rank the mold claims by evidence grade. The question here is narrower: what a mycotoxin result can prove about your terrain, and what to repair instead of measure.

Why a positive mycotoxin test proves so little

A laboratory value means something only against a distribution of healthy, unexposed people measured the same way. These panels supply none. There is no FDA-approved test for mycotoxins in human urine, a 2024 European guideline finds no useful validated procedure for clinical diagnosis, and American medical toxicology rejects antibody versions as well. A number without a reference range is neither low nor high. It is simply printed.

Presence versus dose: what a real measurement looks like

The version that means something came from an obstetric cohort, not a mold clinic. Fifty pregnant women at one academic center were sampled at four points, with blood and spot urine analyzed by mass spectrometry. Repeated sampling matters because these compounds clear fast, so one urine mostly reflects recent meals.

Almost everyone carried something. Serum citrinin appeared in 32% of samples at a median of 0.02 ng/mL, urinary alternariol monomethyl ether in 69% and zearalenone in 63%. Aflatoxin, the compound with the worst reputation, was not detected in any sample.

Then intakes were held against published safety limits. On average across the sampling points, 28% of the women exceeded the tolerable daily intake for deoxynivalenol and 2% for zearalenone. Against the human biomonitoring guidance value, deoxynivalenol exceedance rose to 48%. Every sample with quantified ochratoxin A had a margin of exposure for cancer effects below 10,000, a flag for possible concern. That is a census turned into a dose. Its ceiling: pregnant women, food as the route, no health outcome measured, and not one damp basement.

Where the dose in your body comes from

The 2025 American toxicology position names diet as the most important source of mycotoxin exposure and models inhaled doses in moldy buildings at orders of magnitude below harmful thresholds. So a urine result is partly a record of what you ate, with grains carrying most of it. Read any single number as a blend of plate and place.

The terrain argument sits beneath that. Mycotoxins compromise the intestinal barrier across its physical, mucus, immune and microbial layers, shown mainly in cell and animal models. In Nigerian infants, stool mycotoxin levels tracked with microbiome composition, and which compounds appeared depended on whether stool, urine or breast milk was sampled. The barrier is where the first brain meets the outside world, and metaflammation begins at that wall long before a lab names a toxin.

The markers sold with the diagnosis

The framework behind these panels adds a blood picture: low alpha-melanocyte-stimulating hormone plus a rise in at least one of TGF-beta 1, C4a and MMP-9. That is falsifiable, to its credit, and outside the originating group it stands neither confirmed nor refuted.

The biology it borrows is genuine. MSH damps the fever and inflammatory effects of cytokines and cut endotoxin-driven IL-1 and TNF in whole blood. But it moves wherever illness moves: up in healthy volunteers given endotoxin, down in sepsis, higher in advanced HIV and in the more inflamed arthritis, lower in healthy older people than the young. No reference interval, assay standardization or cross-laboratory comparison exists. A value with no distribution behind it cannot be called low.

In the primary cholestyramine trial, MSH was abnormal in 25 of the 28 who consented, while the allergy marker IgE was abnormal in just 1, and MSH was never re-measured after treatment. The supporters’ own 2024 review counts ten papers from one group and two randomized trials of 8 and 13 subjects. Its claim that the illness can affect up to 25% of the population is a susceptibility estimate with no confidence interval, and two of its three authors testify as expert witnesses in these cases.

The incentives are easy to trace. A panel, a protocol and a lawsuit are each billable. Drying a foundation is a cost the landlord would rather defer. Follow the invoice and you can predict which claims get marketed and which repair gets postponed.

What earns its place: the clay, then the building

Here the tiers turn over. In Ghana, 177 people at high risk of dietary aflatoxin were randomized to 3.0 g or 1.5 g of calcium montmorillonite clay, or placebo, daily for three months. Compliance ran above 97%. Nothing separated at one month. At three months, serum aflatoxin-albumin adducts fell in both dose groups and urinary aflatoxin M1 fell by up to 58% at the high dose, while serum vitamins A and E stayed comparable. The same clay cut urinary fumonisin B1 by more than 90% at the high dose in humans.

Read that as narrowly as the authors did. The clay reduced absorption of aflatoxin being eaten. It did not show clearance of anything stored, and it was a characterized, contaminant-screened clay given under supervision, not a shelf detox product. Cholestyramine binds bile acids, and the bile circuit it interrupts is not proof a toxin was riding in it. Anyone already taking it should raise the question with the prescribing physician rather than changing course alone.

The building is the repair with human outcome data. A Cochrane review pooling 12 studies and 8,028 participants found moderate- to very low-quality evidence that repairing mold-damaged homes and offices reduces asthma-related symptoms and respiratory infections in adults. One included study found no difference between full and partial repair, and no study collected a gut outcome. Fix the wall anyway.

How to measure your own terrain instead

The best instrument is already yours. Record dates, not impressions: when symptoms shift, where you slept, what changed in the house beforehand. Pollen can mimic a building on a seasonal calendar, so the dates matter. Then measure what repair can move. A metabolic audit tests whether your body can heal, testing before treating keeps each number tied to a decision, and rebuilding the gut after antibiotics is the next terrain problem. Every study cited here is in the Deep Dive, with full numbers and what each one does not show.

Frequently asked questions

Are urine mycotoxin tests FDA approved?

No. There is no FDA-approved test for mycotoxins in human urine, and the laboratory rules these panels run under do not address whether the assay measures what it claims. European and American specialty bodies both call the available tests unvalidated for clinical diagnosis. A result still gets printed, just without a healthy reference distribution. The mold diseases that are firmly established are immune ones, diagnosed differently.

What does a positive mycotoxin test mean if everyone has them?

On its own, very little. Low levels sit in ordinary food and so in healthy urine, and a positive only means a value landed above a cutoff somebody chose. The meaningful version compares estimated intake with a published safety limit, which is how the pregnancy cohort showed who stood over the line. How an inflammation biomarker earns clinical meaning shows the standard these panels miss.

Do mold binders remove mycotoxins from the body?

The best binder evidence is a clay trial in Ghanaians eating aflatoxin-contaminated food, where exposure biomarkers fell at three months without depleting vitamins A and E. That shows reduced absorption of a toxin being eaten, not removal of a stored one, and the trial clay was a characterized product. Why one treatment works in one terrain and fails in another applies here too.

Is MSH a reliable marker for mold illness?

Not yet. Alpha-MSH is measurable and biologically real, but it rises with endotoxin, falls in sepsis and drifts lower with healthy aging, so a single value has no fixed meaning. No reference interval or cross-laboratory standard has been published, which makes a low reading an opinion about a number. Inflammaging explains why so many inflammatory signals drift with age.

Does mold remediation improve gut health?

Nobody has measured it. The controlled remediation trials scored wheeze, rhinitis, asthma days and infections, and none collected a gut outcome. The study that would answer it randomizes houses rather than patients and measures calprotectin and flare rates. Until then, remediation rests on airway data and on a precaution every guideline shares. What refills a gut from above is the next place to look.

Sources

1. Krausová, M., Ayeni, K. I., Gu, Y., Borutzki, Y., O’Bryan, J., Perley, L., Silasi, M., Wisgrill, L., Johnson, C. H., & Warth, B. (2024). Longitudinal biomonitoring of mycotoxin exposure during pregnancy in the Yale Pregnancy Outcome Prediction Study. Environment International, 194, 109081. https://doi.org/10.1016/j.envint.2024.109081
2. Kawamoto, M., & Page, E. (2015). Notes from the field: Use of unvalidated urine mycotoxin tests for the clinical diagnosis of illness — United States, 2014. MMWR. Morbidity and Mortality Weekly Report, 64(6), 157-158. https://pubmed.ncbi.nlm.nih.gov/25695323/
3. Leikin, J., Holland, M. G., Kurt, T. L., McKay, C. A., & Stolbach, A. I. (American College of Medical Toxicology). (2025). ACMT position statement: Medical toxicology considerations in the diagnosis and treatment of patients with concerns about mold-related inhalation exposures. https://www.acmt.net/wp-content/uploads/2025/08/PS_250813_ACMT-Position-Statement-Mold-Related-Inhalation-Exposures.pdf
4. Catania, A., Airaghi, L., Garofalo, L., Cutuli, M., & Lipton, J. M. (1998). The neuropeptide alpha-MSH in HIV infection and other disorders in humans. Annals of the New York Academy of Sciences, 840, 848-856. https://doi.org/10.1111/j.1749-6632.1998.tb09622.x
5. Dooley, M., Vukelic, A., & Jim, L. (2024). Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. Annals of Medicine and Surgery (2012), 86(12), 7248-7254. https://doi.org/10.1097/MS9.0000000000002718
6. Ayeni, K. I., Seki, D., Pjevac, P., Hausmann, B., Krausová, M., Braun, D., Wisgrill, L., Berry, D., Warth, B., & Ezekiel, C. N. (2024). Biomonitoring of dietary mycotoxin exposure and associated impact on the gut microbiome in Nigerian infants. Environmental Science & Technology, 58(5), 2236-2246. https://doi.org/10.1021/acs.est.3c07786
7. Afriyie-Gyawu, E., Ankrah, N.-A., Huebner, H. J., Ofosuhene, M., Kumi, J., Johnson, N. M., Tang, L., Xu, L., Jolly, P. E., Ellis, W. O., Ofori-Adjei, D., Williams, J. H., Wang, J.-S., & Phillips, T. D. (2007). NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis. I. Study design and clinical outcomes. Food Additives & Contaminants. Part A, 25(1), 76-87. https://doi.org/10.1080/02652030701458105
8. Wang, P., Afriyie-Gyawu, E., Tang, Y., Johnson, N. M., Xu, L., Tang, L., Huebner, H. J., Ankrah, N.-A., Ofori-Adjei, D., Ellis, W., Jolly, P. E., Williams, J. H., Wang, J.-S., & Phillips, T. D. (2008). NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis: II. Reduction in biomarkers of aflatoxin exposure in blood and urine. Food Additives & Contaminants. Part A, 25(5), 622-634. https://doi.org/10.1080/02652030701598694
9. Robinson, A., Johnson, N. M., Strey, A., Taylor, J. F., Marroquin-Cardona, A., Mitchell, N. J., Afriyie-Gyawu, E., Ankrah, N. A., Williams, J. H., Wang, J. S., Jolly, P. E., Nachman, R. J., & Phillips, T. D. (2012). Calcium montmorillonite clay reduces urinary biomarkers of fumonisin B1 exposure in rats and humans. Food Additives & Contaminants. Part A, 29(5), 809-818. https://doi.org/10.1080/19440049.2011.651628
10. Sauni, R., Verbeek, J. H., Uitti, J., Jauhiainen, M., Kreiss, K., & Sigsgaard, T. (2015). Remediating buildings damaged by dampness and mould for preventing or reducing respiratory tract symptoms, infections and asthma. Cochrane Database of Systematic Reviews, 2015(2), CD007897. https://doi.org/10.1002/14651858.CD007897.pub3

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 26 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.